Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltobulin in advanced colorectal cancer
NCT00080834Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2004
- Primary completion
- Aug 2006
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of taltobulin in colorectal cancer (CRC), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Objective Tumor Response Rate. Started Feb 2004; status: completed.
02
Drugs
taltobulin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00080834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080834.